Physician profile
Vanessa N Becker
NPI 1861496440
$6,169.67
in general payments reported to CMS, 2019-2025
31 companies · $1,764 in 2025
The $1,764 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,178 · 2023: $1,291 · 2024: $1,937 · 2025: $1,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,915 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,914.97 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,362.35 | 2022-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,300.38 | 2022-2025 | |
| Janssen Biotech, INC. | $962.67 | 2022-2025 | Stelara, Tremfya, Simponi |
| Lilly USA, LLC | $316.42 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $263.51 | 2022-2025 | Livdelzi |
| Phathom Pharmaceuticals, INC. | $250.97 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $209.87 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $149.62 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $133.50 | 2022-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $105.23 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.11 | 2022-2025 | Eohilia, Entyvio, Gattex |
| Ferring Pharmaceuticals INC. | $101.08 | 2022-2023 | Rebyota |
| Evoke Pharma, INC. | $101.05 | 2022-2025 | Gimoti |
| Ironwood Pharmaceuticals, INC | $96.88 | 2023-2024 | Linzess |
| Pfizer INC. | $84.21 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $78.28 | 2022-2023 | Talicia |
| Merck Sharp & Dohme LLC | $71.82 | 2022-2024 | Dificid |
| Celltrion USA INC. | $61.34 | 2024-2025 | Vegzelma |
| Madrigal Pharmaceuticals | $58.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $57.56 | 2022-2024 | |
| Novo Nordisk INC | $54.43 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $48.96 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $37.86 | 2022-2024 | Suflave |
| Janssen Pharmaceuticals, INC | $29.67 | 2022 | |
| Fresenius Kabi USA, LLC | $23.66 | 2024 | Idacio |
| Vivus LLC | $23.13 | 2025 | Pancreaze |
| American Regent | $18.82 | 2025 | Injectafer |
| Shield Therapeutics INC | $17.12 | 2024 | |
| Azurity Pharmaceuticals, INC. | $16.13 | 2025 | Suflave |
| Regeneron Healthcare Solutions, INC. | $15.89 | 2022 | |
| Intercept Pharmaceuticals, INC. | $15.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.